652.91
price down icon0.24%   -1.57
after-market Dopo l'orario di chiusura: 652.91
loading
Precedente Chiudi:
$654.48
Aprire:
$650.41
Volume 24 ore:
1.71M
Relative Volume:
1.62
Capitalizzazione di mercato:
$68.01B
Reddito:
$14.21B
Utile/perdita netta:
$4.46B
Rapporto P/E:
16.45
EPS:
39.6877
Flusso di cassa netto:
$3.56B
1 W Prestazione:
+11.66%
1M Prestazione:
+16.44%
6M Prestazione:
+14.77%
1 anno Prestazione:
-29.59%
Intervallo 1D:
Value
$637.66
$659.98
Intervallo di 1 settimana:
Value
$572.75
$659.98
Portata 52W:
Value
$476.49
$935.86

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,207
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2025-08-01
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Confronta REGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
12:01 PM

Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha

12:01 PM
pulisher
11:04 AM

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech

11:04 AM
pulisher
10:54 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat

10:54 AM
pulisher
10:45 AM

Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus

10:45 AM
pulisher
10:22 AM

Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News

10:22 AM
pulisher
10:11 AM

Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus

10:11 AM
pulisher
09:35 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat

09:35 AM
pulisher
09:35 AM

Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus

09:35 AM
pulisher
08:57 AM

FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues - BioSpace

08:57 AM
pulisher
08:36 AM

Regeneron Pharmaceuticals (REGN) Analyst Rating Update: Price Ta - GuruFocus

08:36 AM
pulisher
08:33 AM

RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating - MarketScreener

08:33 AM
pulisher
08:32 AM

Opko Health’s ModeX enters license, collab agreement with Regeneron - TipRanks

08:32 AM
pulisher
08:29 AM

FDA rejects Regeneron’s Eylea HD amid filling facility woes - Pharmaceutical Technology

08:29 AM
pulisher
08:21 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript - Insider Monkey

08:21 AM
pulisher
08:04 AM

Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com

08:04 AM
pulisher
08:00 AM

OPKO Health (NASDAQ: OPK) in Regeneron deal: $7M upfront, up to $200M per molecule - Stock Titan

08:00 AM
pulisher
07:23 AM

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $767 From $756, Maintains Overweight Rating - MarketScreener

07:23 AM
pulisher
07:20 AM

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $725 From $640, Maintains Outperform Rating - MarketScreener

07:20 AM
pulisher
07:13 AM

Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $700 From $660, Maintains Buy Rating - MarketScreener

07:13 AM
pulisher
07:08 AM

General American Investors Co. Inc. Sells 5,000 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:08 AM
pulisher
07:07 AM

TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $780, Maintains Buy Rating - MarketScreener

07:07 AM
pulisher
07:07 AM

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $788 From $785, Maintains Buy Rating - MarketScreener

07:07 AM
pulisher
06:12 AM

Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More - BioSpace

06:12 AM
pulisher
05:16 AM

Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsBull Run & Stock Timing and Entry Methods - newser.com

05:16 AM
pulisher
04:41 AM

Teacher Retirement System of Texas Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:41 AM
pulisher
04:22 AM

OVERSEA CHINESE BANKING Corp Ltd Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:22 AM
pulisher
04:20 AM

Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 Price Swings & Verified Entry Point Signals - newser.com

04:20 AM
pulisher
02:04 AM

Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges - TipRanks

02:04 AM
pulisher
12:20 PM

Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus

12:20 PM
pulisher
12:18 PM

Regeneron Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks

12:18 PM
pulisher
Oct 28, 2025

Regeneron Earnings Call: Strong Growth Amid Challenges - TipRanks

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts - Investor's Business Daily

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron (REGN) Q3 2025 Earnings Call Transcript - The Motley Fool

Oct 28, 2025
pulisher
Oct 28, 2025

Big Names In Health Care Diverge As Market Stumbles - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025. - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

JPMorgan Raises Price Target on Regeneron Pharmaceuticals to $850 From $800 - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Pharma Boom: Regeneron’s Latest Innovations - StocksToTrade

Oct 28, 2025
pulisher
Oct 28, 2025

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase - Nasdaq

Oct 28, 2025
pulisher
Oct 28, 2025

FDA rebuff puts new dent in Regeneron's bid to crank up Eylea HD rollout - FirstWord Pharma

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron Pharmaceuticals (REGN) Reports Strong Q3 Growth Driven by Key Products - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Jefferies & Co Adjusts Regeneron Pharmaceuticals Price Target to $870 From $831 - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron tops quarterly estimates, plans to resubmit Eylea application - Reuters

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron (REGN) Soars on Strong Q3 Performance Driven by Dupixent Growth - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron rises as 3rd-qrt results beat expectations - The Pharma Letter

Oct 28, 2025
pulisher
Oct 28, 2025

Why Are Regeneron (REGN) Shares Soaring Today - The Globe and Mail

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron reports another manufacturing-related rejection for Eylea HD, but says help is on the way - Fierce Pharma

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron rises as Q3 results beat on both lines driven by Dupixent growth - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron (REGN) Surges on Strong Q3 Earnings and Dupixent Sales - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron Q3 2025 slides: Dupixent drives growth as pipeline expands - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Regeneron discloses CRL; AbbVie stops work on Dragonfly asset - Endpoints News

Oct 28, 2025

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$481.59
price up icon 1.19%
$821.97
price down icon 1.72%
$166.95
price up icon 1.00%
biotechnology ONC
$314.85
price down icon 0.63%
$417.21
price down icon 1.23%
Capitalizzazione:     |  Volume (24 ore):